Abstract
Magnesium offers theoretic vascular and neuroprotective benefits for patients with subarachnoid hemorrhage. An electronic literature search was conducted to identify original research studies describing intravenous magnesium treatment in patients with SAH published in English between January 1990 and October 2010. Seventeen articles were identified and reviewed, including one phase III randomized-controlled clinical trial and six phase II randomized-controlled trials. Study quality was low for most of the included studies, with the phase III trial considered to be of moderate quality. Due to inconsistently reported benefits and the occurrence of side effects, phase II data suggested that intravenous magnesium for SAH provided either no overall net benefit or uncertain trade-offs. Benefit was likewise not supported in the single phase III clinical trial.
Similar content being viewed by others
References
Saddeh M. Action of magnesium sulfate in the treatment of preeclampsia-eclampsia. Stroke. 1989;20:1273–5.
Taccone FS. Vasodilation and neuroprotection: the magnesium saga in subarachnoid hemorrhage. Crit Care Med. 2010;38:1382–3.
Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. Neuroprotective effects of preischemia intra-arterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg. 1996;85:117–24.
van den Bergh WM, Dijkhuizen RM, Rnkel GJ. Potentials of magnesium treatment in subarachnoid hemorrhage. Magnes Res. 2004;17:301–13.
Ortega-Gutierrez S, Mayer SA. Is the magnesium era for aneurysmal subarachnoid hemorrhage over? Curr Neurol Neurosci Rep. 2010;10:420–2.
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
Wong GKC, Poon WS, Chan MTV, Boet R, Gin T, Ng SCP, Zee BCY, For the IMASH Investigators. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke. 2010;41:921–6.
Westermaier T, Stetter C, Vince GH, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. 2010;38:1284–90.
Wong GKC, Chan MTV, Boet R, Poon WS, Gin T. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol. 2006;18:142–8.
van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36:1011–5.
Schmid-Elsaesser R, Kunz M, Zausinger S, Prueckner S, Briegel J, Steiger HJ. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. Neurosurgery. 2006;58:1054–65.
Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol. 2008;69:33–9.
Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;96:510–4.
van den Bergh WM, Albrecht KW, Berkelbach JW, van der Sprenkel B, Rinkel GJE. Magnesium therapy after aneurysmal subarachnoid haemorrhage dose-finding study for long term treatment. Acta Neurochir. 2003;145:195–9.
Stippler M, Crago E, Levy EI, et al. Magnesium infusion for vasospasm prophylaxis after subarachnoid hemorrhage. J Neurosurg. 2006;105:723–9.
Boet R, Mee E. Magnesium sulfate in the management of patients with Fisher Grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery. 2000;47:602–7.
Brewer RP, Parra A, Lynch J, Chilukuri V, Borel CO. Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2001;13:202–6.
Mori K, Yamamoto T, Nakao Y, et al. Initial clinical experience of vasodilatory effect of intracisternal infusion of magnesium sulfate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2009;49:139–45.
Friedlich D, Agner C, Boulos AS, et al. Retrospective analysis of parenteral magnesium sulfate administration in decreased incidence of clinical and neuroradiological cerebral vasospasm: a single center experience. Neurol Res. 2009;31:621–5.
Kerz T, Victor A, Beyer C, Trapp I, Heid F, Reisch R. A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ischemia and mortality. Neurol Res. 2008;30:893–7.
Yahia AM, Kirmani JF, Qureshi AI, Guterman LR, Hopkins LN. The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2005;3:16–23.
Shah QA, Memon MZ, Suri MFK, et al. Super-selective intra-arterial magnesium sulfate in combination with nicardipine for the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Neurocrit Care. 2009;11:190–8.
Barile M, van de Wyngaert F, Mbia JJE, et al. Intravenous magnesium sulfate administration in a patient with refractory vasospasm following subarachnoid hemorrhage. Intensive Care Med. 2003;29:1182–5.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The Participants in the International Multidisciplinary Consensus Conference: Michael N. Diringer, Thomas P. Bleck, Nicolas Bruder, E. Sander Connolly, Jr., Giuseppe Citerio, Daryl Gress, Daniel Hanggi, J. Claude Hemphill, III, MAS, Brian Hoh, Giuseppe Lanzino, Peter Le Roux, David Menon, Alejandro Rabinstein, Erich Schmutzhard, Lori Shutter, Nino Stocchetti, Jose Suarez, Miriam Treggiari, MY Tseng, Mervyn Vergouwen, Paul Vespa, Stephan Wolf, Gregory J. Zipfel.
Rights and permissions
About this article
Cite this article
Suarez, J.I., The Participants in the International Multidisciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Magnesium Sulfate Administration in Subarachnoid Hemorrhage. Neurocrit Care 15, 302–307 (2011). https://doi.org/10.1007/s12028-011-9603-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-011-9603-y